Author: Kathir J

Driving a More Transparent and Efficient Future for Music Investing Through AI, Portfolio Products, and Blockchain

As the global digital music industry continues to expand and music assets gain recognition as an emerging investment class, CadenzaX Music is redefining how investors participate in music investing through technology innovation and product evolution.
 
Founded in 2020 and headquartered in Colorado, USA, CadenzaX Music is a music technology and digital asset services company dedicated to building a smarter, more transparent, and more efficient infrastructure. Its mission is to transform music assets—once dominated by a small number of institutions—into an accessible and understandable asset class for a broader audience.
 
Recently, the company unveiled its latest advancements across three core areas: AI-powered market analytics, basket-based music investment products, and a blockchain-enabled fast settlement system, further strengthening its leadership in the digital music asset space.

Advancing Music Asset Digitalization
 
Since its founding, CadenzaX Music has focused on the digital transformation of music assets, spanning research, system development, and global service capabilities.
 
Leveraging its U.S. base alongside a global perspective, the company has built an integrated platform covering market analysis, asset screening, portfolio construction, revenue distribution, and data transparency.
 
CadenzaX Music operates with a clear philosophy: technology drives growth, rules build trust, and transparency enhances user experience. The platform aims not only to present opportunities but also to help users understand underlying logic, interpret data, and make informed decisions.
 
To support this vision, the company continues to strengthen capabilities in data modeling, asset research, diversification strategies, on-chain verification, and settlement efficiency, laying the foundation for long-term trust.

AI-Powered Market Analytics
 
Traditional music asset analysis has often relied on fragmented data, manual interpretation, and delayed insights, limiting efficiency and accessibility.
 
CadenzaX Music addresses these challenges by integrating AI into global music market analysis. Its system evaluates multiple dimensions—including streaming trends, regional demand shifts, catalogue lifecycles, historical performance patterns, user behavior, and market signals—providing a more structured and data-driven understanding of asset value.
 
Compared to conventional methods, the AI system processes large-scale data more efficiently and identifies trends faster, delivering clearer and more actionable insights. This helps reduce information asymmetry and supports more rational, data-driven investment decisions.

Basket-Based Investment Products
 
While music assets offer strong potential, individual track performance can vary due to changing market preferences and lifecycle dynamics.
 
To address this, CadenzaX Music has introduced basket-based investment products, designed to enhance diversification and reduce single-asset risk. By combining songs across different styles, markets, and lifecycle stages, these portfolios create a more balanced investment structure.
 
This approach shifts participation from single-track selection to portfolio-based allocation, aligning with diversification principles widely used in mature financial markets. It simplifies access while promoting a more sustainable and strategic investment model.
 
For investors, this represents a transition from chasing individual hits to building long-term diversified portfolios.

Blockchain-Based Fast Settlement
 
Traditional royalty settlement systems are often characterized by long cycles, multiple intermediaries, and limited transparency.
 
CadenzaX Music addresses these issues with a blockchain-based fast settlement system, designed to standardize transactions, revenue allocation, and settlement processes through a more advanced digital infrastructure.
 
Each transaction and distribution record is securely documented, reducing ambiguity and improving clarity. For users, this results in:
clearer visibility of income sources
traceable distribution pathways
greater transparency in settlement
 
Beyond efficiency, the system enhances trust. In a data-driven market, mechanisms that are visible, verifiable, and reliable are essential. CadenzaX Music aims to deliver a more secure and transparent experience while addressing long-standing inefficiencies in traditional systems.

Building Trust Through Expertise and Long-Term Vision
 
CadenzaX Music brings together expertise from music, data science, finance, and technology. The company believes the future of music assets depends not only on value creation but also on the integration of technology, governance, and operational excellence.
 
Since its inception, the company has maintained a long-term focus—continuously improving infrastructure, refining products, and enhancing efficiency and compliance. Across all processes, it prioritizes clear rules, transparent systems, and consistent execution.
 
True competitiveness, the company believes, lies in the ability to consistently deliver clarity, reliability, and efficiency, rather than simply appearing advanced.

Shaping the Future of Music Investing
 
Looking ahead, CadenzaX Music will continue to develop across four key areas:
intelligent analytics, portfolio structuring, transparent settlement, and digital recordkeeping.
 
Through ongoing innovation, the company aims to promote a more standardized, transparent, and digitally driven music investment market.
 
With technology and global expansion working together, CadenzaX Music is making music investing more accessible, more understandable, and more trustworthy for long-term participation.

About CadenzaX Music
 
CadenzaX Music is an innovative company focused on the digital analysis and settlement of music assets. Founded in 2020 and headquartered in Colorado, USA, the company leverages AI analytics, portfolio-based investment products, and blockchain settlement systems to enhance transparency, efficiency, and user experience in the global music market.
 
Driven by technology, guided by transparency, and centered on users, CadenzaX Music continues to build a more professional, efficient, and trusted music asset ecosystem.

 

Hong Kong – In the complex and ever-changing global economic and trade environment, Hong Kong’s status as an international financial center remains pivotal. To help enterprises more effectively connect with global capital and convey brand value, renowned media service provider SeaPRwire (https://seaprwire.com) announced today that it has further consolidated and expanded its media distribution network in Hong Kong and the Greater China region. This strategic move will significantly enhance corporate financial PR efficiency and the depth of brand exposure in this region.

The Greater China region, particularly the Hong Kong market, gathers top-tier global investment institutions, analysts, and financial media. SeaPRwire’s network consolidation this time focuses on opening up a fast track “from information release to capital attention.” The platform not only strengthened cooperation with local mainstream Chinese and English financial newspapers, magazines, and high-traffic financial portals in Hong Kong but also deeply integrated professional financial information terminals radiating across the Greater China region. This means that corporate financial reports, financing information, or major strategic adjustments released by enterprises can be pushed to the desks of professional investors with extremely high priority.

Furthermore, targeting the increasingly booming technological innovation and new consumption waves in the Greater China region, SeaPRwire simultaneously expanded its media matrix across multiple vertical fields such as technology, venture capital, fashion, and health. Whether it is a unicorn enterprise seeking listing voice in Hong Kong or a multinational brand hoping to expand business in the mainland and the Greater Bay Area, all can achieve precise penetration of target audiences through SeaPRwire’s customized distribution links.

“Hong Kong is not just a distribution window; it is a vital bridge for global capital to perceive China and for Chinese enterprises to go global,” pointed out SeaPRwire’s head of Greater China. “By consolidating this core network, we aim to provide clients with more deterministic communication results, leveraging authoritative media endorsements and extensive channel coverage to escort enterprises’ business voyages in the Greater China region.”

About SeaPRwire

SeaPRwire is Asia’s leading AI-driven earned media management platform, purpose-built to empower PR and communications professionals. Through its flagship Branding-Insight Program, the platform connects clients to over 80,000 journalists and an influencer matrix reaching 300 million followers. Leveraging advanced AI, SeaPRwire helps users identify media targets, personalize pitches, and measure PR impact across key APAC markets, including Japan, China, Korea, and Southeast Asia.

Media Contact

Company: SeaPRwire

Contact: Media Relations Team

Email: cs@seaprwire.com

Website: https://seaprwire.com

CGTN published an article on the Boao Forum for Asia Annual Conference 2026, highlighting Asia’s positive economic outlook and its crucial role in global growth. Showcasing China’s efforts to strengthen regional and multilateral collaboration, the article underscores the forum’s importance as a platform for dialogue and cooperation, and highlights the need for Asian countries to work together to address shared challenges and build a better future.

Asia’s positive economic outlook took center stage at the Boao Forum for Asia (BFA) Annual Conference 2026. Its flagship report, The Asian Economic Outlook and Integration Progress Annual Report 2026, projects the region’s GDP to grow by 4.5% in 2026, reinforcing Asia’s role as a key engine of global growth.

Confidence in Asia’s prospects was further underscored by the robust participation of political and business leaders from around the world at the conference in Boao, south China’s Hainan Province. Attendees gathered to gain deeper insights into China’s trade and investment policies and explore opportunities in the world’s second-largest economy.

Addressing the plenary, Zhao Leji, chairman of the National People’s Congress Standing Committee, described the forum as a prestigious platform for promoting exchanges, collaboration and common development among Asian nations and the wider world. He noted that China stands ready to work with all parties to inject greater vitality and stronger impetus into the region’s development.

Enhancing cooperation amid shared challenges

According to the flagship report, Asia’s share of global GDP (in purchasing power parity terms) is expected to rise from 49.2% in 2025 to 49.7% in 2026, reaffirming its central role in the world economy. Meanwhile, intra-regional trade dependence increased from 56.3% in 2023 to 57.2% in 2024, signaling deepening economic integration.

In contrast, the global economy faces a sluggish recovery, rising unilateralism and protectionism, and mounting pressure to restructure industrial and supply chains. The Organization for Economic Co-operation and Development (OECD) projects global growth to slow to 2.9% in 2026, down from 3.3% in 2025.

In a virtual keynote speech, Kim Min-seok, South Korea’s prime minister, called for greater solidarity among Asian countries in the face of uncertainty driven by regional conflicts, technological disruption, supply chain shifts and demographic changes.

Over the past decades, Asian economies have strengthened regional cooperation and advanced along a path of mutual benefit. In 2025, trade between China and the Association of Southeast Asian Nations (ASEAN) reached 7.55 trillion yuan (around $1.99 trillion), up 8% year on year, according to the General Administration of Customs of China (GACC).

Chi Fulin, president of the China Institute for Reform and Development, noted that this growth reflects increasingly close ties between China and ASEAN under the framework of the Regional Comprehensive Economic Partnership (RCEP).

Sharing opportunities for a better future

At China’s annual Two Sessions in March, the country sent a clear signal of its commitment to opening-up, multilateral cooperation and mutual benefit. In 2025, China’s total goods imports reached a record 18.48 trillion yuan, accounting for roughly 10% of the global total and reinforcing its position as the world’s second-largest import market, according to GACC.

China continues to translate the advantages of its vast domestic market into opportunities for global businesses. With an average annual growth rate of 5.4% and an economy exceeding 140 trillion yuan, it contributes around 30% of global growth and remains a vital engine of the world economy, Zhao said.

Meanwhile, China’s push to develop new quality productive forces – particularly in artificial intelligence and robotics – is creating fresh opportunities across industries. A range of intelligent robots showcased at the forum drew significant attention from participants.

In his remarks, Singaporean Prime Minister Lawrence Wong said China is contributing to global development through its growing strength and taking on greater responsibilities in the international system. He added that Singapore remains confident in China’s long-term prospects and supports its deeper participation in regional economic frameworks.

Marking its 25th anniversary and coinciding with the launch of China’s 15th Five-Year Plan (2026–2030), the forum comes at a pivotal moment. In his speech, Zhao called on participants of the forum to forge ahead with concerted efforts and enhance cooperation to address global challenges, bring win-win results and create a better future.

https://news.cgtn.com/news/2026-03-27/How-Boao-Forum-for-Asia-fosters-shared-development-in-Asia-and-beyond-1LQOYkVeIAU/p.html

SINGAPORE  – 18/03/2026 – (SeaPRwire) – AdsDrama, a digital platform focused on short drama content and online advertising, has introduced an ecosystem designed to integrate content distribution, advertising services, and user participation. The launch comes as short-form video continues to expand globally, shaping how content is consumed and monetized across digital channels.

What Is AdsDrama?

AdsDrama (https://www.adsdrama.com) is a platform centered on short drama marketing and digital advertising monetization. It connects content creators, advertisers, and users through a structured system intended to support content distribution and advertising delivery.

Unlike traditional content platforms where users primarily consume media, AdsDrama incorporates a participation-based model. Users can engage with certain platform functions related to content promotion and advertising processes.

The platform operates through a structured framework designed to simplify user access and participation.

User Onboarding

New users can register and access an introductory interface that presents the platform’s core features, including its advertising workflows and operational structure.

This step is intended to provide a general understanding of how the platform functions.

Participation Through Structured Levels

After onboarding, users may choose to access different participation levels. Each level provides access to specific platform features, which may include:

• Defined activity parameters
• Access to advertising-related tasks
• System-based allocation of activities

The platform indicates that certain processes are managed through internal systems that handle distribution and performance tracking.

Automated Advertising System

AdsDrama utilizes a data-driven system to distribute short drama content across various digital channels, including:

• Social media platforms
• Short video networks
• Other online content distribution channels

The platform states that it applies audience targeting and traffic allocation tools to support content visibility.

Revenue Model

According to AdsDrama, the platform incorporates multiple revenue streams as part of its business model:

• Online advertising revenue derived from ad placements and traffic distribution
• Content monetization, including paid access to selected short drama content
• Brand collaborations, such as sponsored content and integrations
• IP commercialization through licensing and content expansion
• Technology services related to advertising delivery and data optimization

The company states that this diversified structure is intended to support ongoing platform development.

• Key Features of AdsDrama
• Data-Driven Optimization

AdsDrama reports that it uses analytics and performance tracking tools to monitor advertising campaigns and refine delivery strategies.

Structured Financial System

The platform describes a multi-layer account system designed to manage user balances, which may include:

• Available balances
• Processing stages
• Pending allocations

This structure is intended to support internal accounting processes and system organization.

Standardized Withdrawal Mechanism

AdsDrama indicates that it applies standardized procedures for withdrawals within its operational framework, aiming to streamline processing and reduce administrative complexity.

Why AdsDrama Is Growing

• Industry trends may help explain the emergence of platforms such as AdsDrama:
• Growth of short-form content, as short video and serialized formats continue to attract broad audiences
• Expansion of digital advertising, with businesses increasing spending on online channels
• Gradual shift toward participation-based models, where users engage beyond passive content consumption

Is AdsDrama Worth Exploring?

AdsDrama may be relevant to individuals and organizations interested in:

• Digital advertising platforms
• Content distribution models
• Emerging forms of online engagement

As with any platform, users are encouraged to review publicly available information and consider potential risks before engaging.

AdsDrama represents an approach that combines short-form content with digital advertising infrastructure and user-facing features. As the digital media landscape continues to evolve, platforms of this kind reflect ongoing experimentation in content distribution and monetization models.

Media contact

Brand: AdsDrama LTD

Contact: Media team

Website: https://www.adsdrama.com

Nicosia, Cyprus – 17/03/2026 – (SeaPRwire) – FinHarbor recently announced a major update to its modular fintech infrastructure platform, expanding its crypto-fiat functionality and introducing a deeper orchestration layer across all modules. The updated platform bundles IBAN accounts, card issuing, payments and crypto-fiat exchange into a single stack, reducing typical launch timelines from more than a year to roughly one month. The company positions the platform as a ready-to-deploy foundation for fintech startups, embedded finance teams and licensed institutions that want to bring a financial product to market without building the entire stack internally.

The problem it addresses

Launching a neobank from scratch is still a long and expensive process. Most teams need 15–20 engineers, more than a year of development, and roughly €1.5–2 million before the first customer can even open an account.

FinHarbor’s approach is to remove much of that upfront work. The platform comes with core components already integrated: pre-built connectors to banking partners for IBAN and account infrastructure, card processing, payment rails, and crypto wallets. In practice, this means companies can start with a working financial product instead of assembling and connecting multiple vendors themselves.

What changed in the new release

The main change in the latest version is the introduction of a unified orchestration layer. Earlier versions of the platform offered modular components that could be connected together. The updated release adds a shared data model, a single audit log and compliance logic that operates across all modules.

Clients now integrate through one API and operate under a single contract, while still keeping the option to replace individual components if needed.

On the crypto side the platform has added extended custody capabilities for clients with specific blockchain integration requirements, broadening the range of supported networks and asset types. The compliance and AML tooling has also been updated, making it easier to configure the system to match each client’s internal policies and risk frameworks across different jurisdictions.

A recent deployment in four weeks

One EU-licensed fintech company recently used the updated platform to launch a full neobank in 28 days, including IBAN accounts, card issuance and crypto-fiat exchange.

The first week focused on core infrastructure: setting up the environment, integrating identity verification through SumSub, and connecting to the banking partner’s IBAN account infrastructure.

During the second week the team activated card issuing and configured the platform’s connections to SEPA, SWIFT, and international payment rails provided by the licensed banking partner.

The third week introduced the crypto layer – custodial wallets, exchange logic and fiat ramps.

The final week was dedicated to integration testing, white-label interface customisation and the production launch.

According to the company, the only noticeable delays were related to compliance approvals with the partner bank – a regulatory step rather than a technical limitation.

Industry perspective

“The new release is based on a simple idea: orchestration matters more than integration,” – said Ilya Podoynitsyn, CEO of FinHarbor.

“Connecting APIs from several vendors isn’t the difficult part. The real challenge is making those components behave like a single product – with unified compliance rules, a shared audit trail and enough flexibility to avoid vendor lock-in. That’s the engineering problem we focused on solving.”

Compliance and target users

The platform includes built-in AML transaction monitoring, sanctions screening and configurable verification tiers. Suspicious activity reports can be generated in formats accepted by regulators, and every system action is recorded in a unified audit log accessible through the admin panel or API.

Companies can operate under their own EMI, PI or VASP licence, or work through a licensed banking partner. The platform is designed to support both models and is aligned with regulatory frameworks such as MiCA and DORA.

FinHarbor says the platform is primarily aimed at three types of clients: fintech startups launching an MVP, companies adding embedded financial services to an existing product, and regulated institutions – including banks or government organisations – that need on-premise infrastructure.

It is best suited for companies looking to launch and iterate quickly on a proven infrastructure, rather than building every component from scratch.

About FinHarbor

FinHarbor is a technical platform provider for launching compliant, modular financial products – from wallets and neobanks to crypto ramps and OTC desks. Built on years of real-world fintech experience, the platform covers onboarding, compliance, wallets, transactions, cards, and reporting, delivered with a microservice-based architecture (ISO/PCI DSS-certified), a robust API layer, and on-premise or cloud-ready deployment. FinHarbor supports fiat-only, crypto-native, and hybrid business models across markets in Europe, MENA, and beyond.

Learn more: www.finharbor.com

Social Links

LinkedIn: https://www.linkedin.com/company/finharbor/

Blog: https://www.finharbor.com/blog

Media contact

Brand: FinHarbor

Contact: Media team

Website:  https://www.finharbor.com/

San Jose, Costa Rica – 17/03/2026 – (SeaPRwire) – Zylo Ecosystem, a multi-product digital platform that combines trading, gaming products, and online services, has announced the launch of its native token ZYLO.

The token will act as the crypto-economic layer of the Zylo ecosystem, connecting various platform products into a unified digital economy. At the same time, the project’s primary focus remains the development of services for a broad audience, including users who are not part of the crypto community.

Everyday Internet Users Remain at the Center of the Ecosystem

Many projects in the crypto industry are built around blockchain technologies from the start and primarily target the Web3 audience.

This approach often limits growth, as such products tend to be understood mainly by users who are already familiar with cryptocurrencies.

Zylo Ecosystem follows a different model.

The ecosystem is designed so that its products are convenient and accessible for everyday internet users who use digital services, play mobile games, and interact with online platforms.

Within this model, the ZYLO token becomes an additional crypto-economic tool that expands the ecosystem’s capabilities without complicating the user experience.

What the Zylo Ecosystem Includes

• The Zylo Ecosystem combines several directions that together form a unified digital and crypto economy.
• Trading Infrastructure
• One of the key elements of the ecosystem is intrade.bar, a trading platform with many years of operational history and an established user community.
• Over time, the platform has built a strong presence in its niche within the CIS market and developed a stable user base.

For most users, the platform remains a fully functional online service. The integration of the ZYLO token introduces additional opportunities within the trading infrastructure and expands the platform’s economic model.

Gaming Products and the GameFi Direction

Gaming is also an important part of the Zylo ecosystem.

Within the ecosystem, the CosmoFox project is being developed — a gaming universe that includes elements of collectibles and an in-game economy.

At the same time, Fox Survivor is being developed as a mobile and web game in the roguelike survival / bullet-hell genre, where players fight waves of enemies, unlock characters, upgrade weapons, and progress through a meta-progression system.

The games are designed as accessible products for a wide audience, while the ZYLO token introduces additional mechanics such as in-game rewards, rare items, premium features, and competitive modes between players.

In certain gameplay scenarios, users will be able to participate in PvP battles, placing bets in ZYLO tokens. The winner receives the tokens staked in the match, creating an additional in-game economy and increasing player engagement.

These mechanics generate additional token circulation within the gaming economy and create organic demand for the token from players.

This approach forms a GameFi economy within the ecosystem, integrated into a broader digital platform.

Digital Services

In addition to trading and gaming products, Zylo is also developing digital services, including VPN solutions and other online tools.

These services add practical utility to the ecosystem and allow the ZYLO token to be used in real user scenarios.

How the ZYLO Token Works

Within the Zylo ecosystem, the token acts as a crypto-economic layer integrated into the platform’s existing products.

The token can be used for:

• purchases within the ecosystem
• gaming mechanics and rewards
• premium features
• special conditions in trading services
• payments for digital services

The Zylo economy also includes deflationary mechanisms, where a portion of tokens is removed from circulation through various burn mechanisms.

As the number of users and services within the ecosystem grows, demand for the token may increase alongside the expansion of its use cases.

Cross-Product Ecosystem Model

One of the key features of Zylo is its cross-product development model, where different products within the ecosystem strengthen each other.

User activity in one service can create value in another. For example, gaming activity may unlock additional opportunities within the ecosystem, while participation in trading services may provide advantages in other products.

This structure enables a more sustainable development model compared to projects built around a single product direction.

Preparation for the First Exchange Listing

Zylo Ecosystem is currently in the final stage of preparation for the first exchange listing of the ZYLO token.

The listing will represent an important step in integrating the ecosystem into the broader crypto market and expanding access to the token for the crypto community.

At the same time, the project’s strategy remains focused primarily on product development and user growth rather than on exchange activity alone.

Founder’s Comment

“We are building products for a broad audience of internet users, not just for the crypto community,” says Alex, founder of Zylo Ecosystem.

“The ZYLO token adds a crypto-economic layer to existing products and allows us to expand the ecosystem’s capabilities without complicating the user experience.”

What’s Next

Following the token launch and the first exchange listing, the Zylo team continues developing the ecosystem, including:

• deeper integration of the token into trading infrastructure
• expansion of the CosmoFox gaming economy
• development of Fox Survivor gameplay
• launching new digital services and expanding them within the ecosystem

At the same time, Zylo is building an ecosystem accelerator, through which new startups will be able to connect to the project’s infrastructure and integrate the ZYLO token into their products.

About Zylo Ecosystem

Zylo Ecosystem is a multi-product digital platform that combines trading services, gaming products, and online tools.

The ecosystem is designed as a convenient digital environment for everyday users, while the ZYLO token forms a crypto-economic layer that connects different services and expands the platform’s capabilities.

This approach allows Zylo to combine the convenience of traditional online services with the possibilities of a Web3 economy.

Social Links

X: https://x.com/Zylo_Ecosystem

Telegram Communication: https://x.com/cosmofoxgame

Telegram Community: https://t.me/ZyloEcosystem

CoinMarketCap: https://coinmarketcap.com/currencies/zylo-ecosystem/

Medium: https://medium.com/zyloecosystem

Media contact

Brand: Zylo

Contact: Media team

Website: http://zylo.io/

Tashkent, Uzbekistan – 16/03/2026 – (SeaPRwire) – FinHarbor recently announced a major update to its modular fintech infrastructure platform, expanding its crypto-fiat functionality and introducing a deeper orchestration layer across all modules. The updated platform bundles IBAN accounts, card issuing, payments and crypto-fiat exchange into a single stack, reducing typical launch timelines from more than a year to roughly one month. The company positions the platform as a ready-to-deploy foundation for fintech startups, embedded finance teams and licensed institutions that want to bring a financial product to market without building the entire stack internally.

The problem it addresses

Launching a neobank from scratch is still a long and expensive process. Most teams need 15–20 engineers, more than a year of development, and roughly €1.5–2 million before the first customer can even open an account.

FinHarbor’s approach is to remove much of that upfront work. The platform comes with core components already integrated: pre-built connectors to banking partners for IBAN and account infrastructure, card processing, payment rails, and crypto wallets. In practice, this means companies can start with a working financial product instead of assembling and connecting multiple vendors themselves.

What changed in the new release

The main change in the latest version is the introduction of a unified orchestration layer. Earlier versions of the platform offered modular components that could be connected together. The updated release adds a shared data model, a single audit log and compliance logic that operates across all modules.

Clients now integrate through one API and operate under a single contract, while still keeping the option to replace individual components if needed.

On the crypto side the platform has added extended custody capabilities for clients with specific blockchain integration requirements, broadening the range of supported networks and asset types. The compliance and AML tooling has also been updated, making it easier to configure the system to match each client’s internal policies and risk frameworks across different jurisdictions.

A recent deployment in four weeks

One EU-licensed fintech company recently used the updated platform to launch a full neobank in 28 days, including IBAN accounts, card issuance and crypto-fiat exchange.

The first week focused on core infrastructure: setting up the environment, integrating identity verification through SumSub, and connecting to the banking partner’s IBAN account infrastructure.

During the second week the team activated card issuing and configured the platform’s connections to SEPA, SWIFT, and international payment rails provided by the licensed banking partner.

The third week introduced the crypto layer – custodial wallets, exchange logic and fiat ramps.

The final week was dedicated to integration testing, white-label interface customisation and the production launch.

According to the company, the only noticeable delays were related to compliance approvals with the partner bank – a regulatory step rather than a technical limitation.

Industry perspective

“The new release is based on a simple idea: orchestration matters more than integration,” – said Ilya Podoynitsyn, CEO of FinHarbor.

“Connecting APIs from several vendors isn’t the difficult part. The real challenge is making those components behave like a single product – with unified compliance rules, a shared audit trail and enough flexibility to avoid vendor lock-in. That’s the engineering problem we focused on solving.”

Compliance and target users

The platform includes built-in AML transaction monitoring, sanctions screening and configurable verification tiers. Suspicious activity reports can be generated in formats accepted by regulators, and every system action is recorded in a unified audit log accessible through the admin panel or API.

Companies can operate under their own EMI, PI or VASP licence, or work through a licensed banking partner. The platform is designed to support both models and is aligned with regulatory frameworks such as MiCA and DORA.

FinHarbor says the platform is primarily aimed at three types of clients: fintech startups launching an MVP, companies adding embedded financial services to an existing product, and regulated institutions – including banks or government organisations – that need on-premise infrastructure.

It is best suited for companies looking to launch and iterate quickly on a proven infrastructure, rather than building every component from scratch.

About FinHarbor

FinHarbor is a technical platform provider for launching compliant, modular financial products – from wallets and neobanks to crypto ramps and OTC desks. Built on years of real-world fintech experience, the platform covers onboarding, compliance, wallets, transactions, cards, and reporting, delivered with a microservice-based architecture (ISO/PCI DSS-certified), a robust API layer, and on-premise or cloud-ready deployment. FinHarbor supports fiat-only, crypto-native, and hybrid business models across markets in Europe, MENA, and beyond.

Learn more: www.finharbor.com

Social Links

LinkedIn: https://www.linkedin.com/company/finharbor/

Blog: https://www.finharbor.com/blog

Media contact

Brand: FinHarbor

Contact: Media team

Website:  https://www.finharbor.com/

 

 

 

 

 

 

replaces the need to copy and paste long hexadecimal wallet addresses.

Adoption of ENS names expanded significantly during the growth of Web3 in 2021 and 2022, when many public figures and entrepreneurs began registering their own .eth identities.

Notable individuals who have used ENS names include Jimmy Fallon (fallon.eth), Paris Hilton (parishilton.eth), Shaquille O’Neal (shaq.eth), Anthony Hopkins (anthonyhopkins.eth), and Snoop Dogg, who is associated with the ENS identity snoopdogg.eth.

Prominent technology leaders have also registered ENS identities, including Vitalik Buterin (vitalik.eth), Alexis Ohanian (alexisohanian.eth), and Tobias Lütke.

Several major brands have also secured ENS domains, including Puma (puma.eth) and Budweiser, which acquired beer.eth as part of its Web3 branding initiatives.

With only 17,576 possible three-letter combinations, short ENS domains remain among the most scarce identifiers within the ecosystem.

Because the “LLC” designation is used by millions of businesses worldwide, a domain such as llc.eth represents one of the few blockchain identifiers that directly corresponds to a real-world legal structure, creating potential applications across digital payments, Web3 identity systems, and on-chain business infrastructure.

 

 

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved for marketing in China by the National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients.

The approval of Desidustat Tablets will further strengthen the Group’s overall layout in the field of nephrology, and synergize with the marketed innovative drug Velphoro (Sucroferric Oxyhydroxide Chewable Tablets, indicated for CKD hyperphosphatemia). Through the efficient linkage of nephrology expert resources and channel networks, the Group is expected to rapidly promote the large-scale clinical application of Desidustat Tablets, providing differentiated treatment options for Chinese CKD patients with renal anaemia and making a positive contribution to the Group’s performance.

More information about Desidustat Tablets and Renal Anaemia

As a novel oral HIF-PHI, the Product’s mechanism of action promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin. Its China Phase III clinical trial has demonstrated positive results. The primary endpoint of the haemoglobin (Hb) mean change from baseline to Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. Results from the extension study demonstrate that the Product can maintain Hb level within the target range over the long term with acceptable safety. In addition, the Product significantly reduces hepcidin levels and ameliorates iron metabolism disorders.

There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China^[1]. Anaemia is one of the frequent complications of CKD, which exhibits a progressively increasing incidence with disease progression. A survey in China showed that the prevalences of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively^[2]. The target-achieving rate (the Hb level reaching the target value (110~120g / L)) has increased to 51.5% for haemodialysis CKD patients with anaemia^[3], but is still only 8.2% for anaemia patients in non-dialysis CKD^[4]. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia.

Desidustat Tablets have been approved for marketing in India.

CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) pursuant to a License Agreement with an effective date of 20 January 2020.

The Group adheres to its core strategy of “innovation-driven”, having established a tiered and multi-dimensional innovation product portfolio with abundant reserves: 7 new drugs have been approved for marketing, 6 are currently under marketing review, and nearly 20 projects are about to initiate or are progressing through clinical trials. Through a dual-engine innovation approach combining collaborative development and in-house R&D, the Group continuously enriches its innovative pipeline centered on first-in-class (FIC) and best-in-class (BIC) products, efficiently advancing clinical development and commercialization. Moving forward, CMS will remain clinical needs-driven to deliver more quality pharmaceutical solutions, steadfastly advancing toward the goal of becoming a specialty-focused, innovation-excellent multinational pharmaceutical enterprise.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

Reference

1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-6

2. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2014 Revised Edition)[J]. Chinese Journal of Nephrology, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.015

3. 19th CSN Critical Care & Blood Purification Congress, Chinese Medical Association (July 2-5, 2025)

4. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2018 Revised Edition)[J]. Chinese Journal of Nephrology, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Website: https://web.cms.net.cn/en/home/

SHENZHEN, CHINA – On 12 March 2026, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health, which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix^®) (the “Product”, marketed as Opzelura^® in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. The prescriptions cover approximately a thousand influential public and private medical institutions in the field of skin health and disease management, including Huashan Hospital, Fudan University, Shanghai Skin Disease Hospital, Dermatology Hospital of Southern Medical University, Second People’s Hospital of Chengdu, The First Bethune Hospital of Jilin University, The Second Xiangya Hospital of Central South University, United Family Healthcare Group, among others*. Meanwhile, the Product has become concurrently accessible via over 1,300 offline drugstores as well as JD.com e-commerce platform. *Hospital rankings are listed in no particular order.

As the first topical JAK inhibitor approved in China for the treatment of vitiligo, ruxolitinib phosphate cream has officially launched its large-scale clinical application today, marking a breakthrough in China’s vitiligo treatment landscape and ushering in a new era of precision targeted therapy for vitiligo. Supported by safety and efficacy fully demonstrated in clinical studies, the Product is expected to bring new hope for repigmentation to millions of vitiligo patients.

The rapid commercialization progress of ruxolitinib phosphate cream underscores strong product operation capabilities of CMS (including Dermavon), while also reflecting the robust supports from China’s regulatory reforms in accelerating patient access to clinically urgently needed innovative drugs. Benefiting from the integrated healthcare ecosystem of the Hainan Free Trade Port and the “Urgently Needed Imported Drugs for Clinical Use” policy, the Product initiated pilot clinical use in August 2023 at Boao Super Hospital within the Boao Lecheng International Medical Tourism Pilot Zone. Pilot usage subsequently expanded to designated medical institutions across the Guangdong–Hong Kong–Macao Greater Bay Area, Beijing-Tianjin region and other regions. In accordance with the relevant regulations of China’s real-world data application pilot project, as well as supported by the Hainan Provincial Medical Products Administration and the Administration of the Boao Lecheng International Medical Tourism Pilot Zone, the Product has accumulated real-world clinical data in China under pilot application, significantly accelerating its clinical, registration and approval timelines. The Product received its Drug Registration Certificate on January 30, 2026 (approval date: January 27, 2026).

Following its approval, in less than 1.5 months (including the Chinese New Year holiday), the initial prescriptions for ruxolitinib phosphate cream have been issued across multiple regions and hospitals, reflecting the highly efficient collaboration and concerted efforts among CMS teams, regulatory authorities and business partners. With robust support from the cross-departmental coordination mechanism of the Beijing Daxing Airport Economic Zone Joint Administrative Committee, once import conditions were met, the Product completed customs clearance approval, sampling and related customs procedures within 24 hours, and obtained the drug testing report within 7 working days, representing efficient execution and acceleration for the innovative drugs in China. During this process, the Beijing Municipal Medical Products Administration proactively provided end-to-end policy guidance; the government service center has efficiently completed customs clearance filing; the Beijing Institute for Drug Control has conducted methodological pre-testing to accelerate timelines for innovative drug, and continuous worked during the Chinese Spring Festival; and Daxing Airport Customs provided specialized pre-guidance on declaration and swiftly completed customs review and release. Through parallel workflows and coordinated execution, all parties collectively pressed the “fast-forward button” for the Product’s commercialization, helping this urgently needed innovative therapy reach patients faster.

As the Product enters the large-scale clinical application stage, it is expected to further strengthen Dermavon’s comprehensive dermatology solutions and brand value. Building on its leadership in skin health, Dermavon will continue to improve accessibility of ruxolitinib phosphate cream to benefit more vitiligo patients and steadfastly safeguard public skin health through innovation.

About Vitiligo

Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. The discolored areas usually get bigger with time and the condition could influence skin on any part of the patients’ body. Vitiligo usually affects the appearance of patients, especially on exposed areas such as the face and neck. According to a study that involved over 1,000 diagnosed vitiligo patients, over 45% of patients have facial involvement, and over 20% of patients have neck involvement^[1].The obvious presence of white patches may make patients feel that their appearance has been compromised, which in turn materially affects their social life, and is associated with a significantly higher incidence of mental health disorders; accordingly, there is an urgent need for effective treatment options for vitiligo^[2].

It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million^[1]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. Ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance.

More Information About Ruxolitinib Phosphate Cream

Ruxolitinib phosphate cream (Opzelura^®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is the first and only drug approved for the repigmentation of non-segmental vitiligo by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)^[3,4]. In the U.S., the Product is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised adult and pediatric patients aged 2 years and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not advisable. In Europe, ruxolitinib phosphate cream is approved for the topical treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. In China, besides vitiligo indication, the product’s NDA for the treatment of mild-to-moderate AD in adults and pediatric patients aged 2 years and older is also under regulatory review, which has been included in the Priority Review List and is expected to accelerate the Product’s AD review process for marketing approval.

The Group, through the subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).

Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream (excluding territories in which exclusive rights have already been licensed), marketed in the United States and Europe as Opzelura^®. Opzelura^® and the Opzelura^® logo are registered trademarks of Incyte.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

Reference:

1. China Insights Consultancy’s industrial report
2. Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis[J]. Journal of the European Academy of Dermatology and Venereology, 2018,32(8):1343-1351. DOI:10.1111/jdv.14739.
3. The U.S. FDA approval information can be found on the Incyte official website, as follows:

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream

4. The EMA approval information can be found on the Incyte official website, as follows:

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Website: https://web.cms.net.cn/en/home/